title: Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration.
abstract: A pharmaceutical grade Japanese traditional medicine, daikenchuto (TU-100), consisting of Japanese pepper, processed ginger, and ginseng, has been widely used for various intestinal disorders in Japan and now under development as a new therapeutic drug in the US. It is suggested that TU-100 ingredients exert pharmacological effects on intestines via two routes, from the luminal side before absorption and the peripheral blood stream after absorption. Therefore, in order to fully understand the pharmacological actions of TU-100, it is critically important to know the intraluminal amounts and forms of ingested TU-100 ingredients. In the present study, after administrating TU-100 to rats, the concentrations of TU-100 ingredients and their conjugates in the peripheral and portal blood and ileal contents were determined by LC-MS/MS. Next, TU-100 was administered to patients with ileostomy bags, but whose small intestines are diagnosed as healthy, and the ingredients/conjugates in the ileal effluent were analyzed. The results suggest that: (1) Pepper ingredients hydroxysanshools are rapidly absorbed and enter systemic circulation, (2) Ginseng ingredients ginsenosides are transported to the colon with the least absorption, (3) Ginger ingredients gingerols are absorbed and some conjugated in the small intestine and transported via the portal vein. While only a small amount of gingerols/gingerol conjugates enter systemic circulation, considerable amounts reappear in the small intestine. Thus, the effect of TU-100 on the intestines is believed to be a composite of multiple actions by multiple compounds supplied via multiple routes.
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Watanabe
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Kaifuchi
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Kushida
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsumoto
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Miwako
authors.initials: M
authors.lastname: Fukutake
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Mitsue
authors.initials: M
authors.lastname: Nishiyama
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co. Ami, Ibaraki, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.affiliation: Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Faculty of Pharmaceutical Sciences, Hokkaido University Sapporo, Hokkaido, Japan ; Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital Sapporo, Hokkaido, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Kono
keywords: Daikenchuto; gingerol; ginsenosides; luminal concentration; shogaol